Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 47Melanoma 23Neoplasm Metastasis 19Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 13Skin Neoplasms 12Head and Neck Neoplasms 10Recurrence 9Carcinoma, Renal Cell 9Prostatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Squamous Cell 8Breast Neoplasms 8Urinary Bladder Neoplasms 7Carcinoma, Merkel Cell 7Triple Negative Breast Neoplasms 6Colonic Neoplasms 6Carcinoma, Basal Cell 6Carcinoma 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Pancreatic Neoplasms 5Stomach Neoplasms 4Sarcoma 4Multiple Myeloma 4Mouth Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4

Interventions

Docetaxel 3Carboplatin 3motexafin gadolinium 2figitumumab 2cemiplimab 2alpha-2'-deoxythioguanosine 2Paclitaxel 2vandetanib 1temoporfin 1tanespimycin 1brigatinib 1Vinorelbine 1Temozolomide 1Radiotherapy 1Radiosurgery 1Pemetrexed 1Oxaliplatin 1Gemcitabine 1Everolimus 1Erlotinib Hydrochloride 1Crizotinib 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Large Cell × cemiplimab × Clear all
NCT05208944 2026-05-13

THIO Sequenced With Cemiplimab in Advanced NSCLC

Maia Biotechnology

Phase 2 Active not recruiting
227 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡